Information Provided By:
Fly News Breaks for September 10, 2019
HCP
Sep 10, 2019 | 07:54 EDT
Argus analyst Jacob Kilstein upgraded HCP to Buy with a price target of $39, saying the company should be able to boost its revenue and net operating income having recently made "sizable" investments in life science and medical office project while also completing its senior housing portfolio operator transitions. The analyst further points to HCP's recent Q2 earnings beat and a high dividend yield that should be attractive to income-oriented investors, adding that its top-of-historical-range earnings multiple of 19.9-times reflects its "improved growth prospects".